BiotechTube

BEAM-301: Single dose of BEAM-301 administered by IV

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease Type Ia

Conditions

Glycogen Storage Disease Type Ia

Trial Timeline

Dec 6, 2024 → Dec 30, 2027

NCT ID
NCT06735755

About BEAM-301: Single dose of BEAM-301 administered by IV

BEAM-301: Single dose of BEAM-301 administered by IV is a phase 1/2 stage product being developed by Beam Therapeutics for Glycogen Storage Disease Type Ia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06735755. Target conditions include Glycogen Storage Disease Type Ia.

What happened to similar drugs?

3 of 7 similar drugs in Glycogen Storage Disease Type Ia were approved

Approved (3) Terminated (0) Active (4)
✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
✅Avalglucosidase alfa (GZ402666)SanofiApproved
✅Avalglucosidase alfaSanofiApproved
🔄avalglucosidase alfaSanofiPhase 3
🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06735755Phase 1/2Recruiting

Competing Products

20 competing products in Glycogen Storage Disease Type Ia

See all competitors
ProductCompanyStageHype Score
mRNA-3745ModernaPhase 2
0
alglucosidase alfaSanofiPre-clinical
26
avalglucosidase alfaSanofiPhase 3
44
MyozymeSanofiPhase 2/3
38
MyozymeSanofiPre-clinical
26
Avalglucosidase AlfaSanofiPhase 2
35
MyozymeSanofiPhase 2/3
38
ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
43
Avalglucosidase alfa (GZ402666)SanofiApproved
47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
39
Alglucosidase alfaSanofiPhase 2
35
Avalglucosidase alfaSanofiApproved
50
MyozymeSanofiPhase 1/2
32
Alglucosidase alfa GZ419829SanofiPre-clinical
30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
26
alglucosidase alfaSanofiPre-clinical
26
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3
34
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
18